Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Conditions
BRAF V600 Mutation · Low-grade Glioma · Low Grade Glioma of Brain · Recurrent Low Grade Glioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Study coordinator (Girish Dhall, MD)Contact: Principal Investigator (Girish Dhall, MD)University of California, San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Sabine Mueller, MD, PhD, MAS)John Hopkins Medical Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Kenneth Cohen, MD, MBA)St. Louis Children's Hospital Washington University in St. Louis, St Louis, Missouri, United States
Contact: Principal Investigator (Mohamed S Abdelbaki, MD)Duke University Medical Center, Durham, North Carolina, United States
Contact: Study coordinator (Daniel Landi, MD)Contact: Principal Investigator (Daniel Landi, MD)St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Principal Investigator (Amar Gajjar, MD)University of Utah, Salt Lake City, Utah, United States
Contact: Study coordinator (Nicholas Whipple, MD, MPH)Contact: Principal Investigator (Nicholas Whipple, MD, MPH)
Study leads
Sabine Mueller, MD, PHD
Principal Investigator
University of California, San Francisco